Information Provided By:
Fly News Breaks for May 8, 2018
ALXN
May 8, 2018 | 15:01 EDT
Piper Jaffray analyst Christopher Raymond says he would be a buyer of Alexion's shares on weakness today as he thinks the market's reaction to what really amounts to "nothing more than a procedural update" from the EPO is "wholly misplaced." The analyst reminds investors that the Soliris composition of matter patent in question already was subject to a first office action rejection in November of last year. This recent news reflects a continuation of that back and forth, and the real revelation on this does not occur till the oral hearing next February, he adds. Raymond reiterates an Overweight rating and $170 price target on the shares.
News For ALXN From the Last 2 Days
There are no results for your query ALXN